Generation and Functional Characterization of Anti-CD19 Chimeric Antigen Receptor-Natural Killer Cells from Human Induced Pluripotent Stem Cells

被引:7
|
作者
Klaihmon, Phatchanat [1 ]
Kang, Xing [1 ]
Issaragrisil, Surapol [1 ,2 ,3 ]
Luanpitpong, Sudjit [1 ,4 ]
机构
[1] Mahidol Univ, Fac Med, Siriraj Ctr Excellence Stem Cell Res, Siriraj Hosp, Bangkok 10700, Thailand
[2] Mahidol Univ, Fac Med, Dept Med, Div Hematol,Siriraj Hosp, Bangkok 10700, Thailand
[3] Wattanosoth Canc Hosp, BDMS Ctr Excellence Hematol, Bangkok 10310, Thailand
[4] Mahidol Univ, Fac Med, Blood Prod & Cellular Immunotherapy Res Grp, Siriraj Hosp, Bangkok 10700, Thailand
关键词
chimeric antigen receptor; induced pluripotent stem cell; natural killer cell; anti-CD19; CAR; leukemia; CAR-NK; NK differentiation; DIFFERENTIATION; CANCER; MEMORY;
D O I
10.3390/ijms241310508
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Natural killer (NK) cells are a part of innate immunity that can be activated rapidly in response to malignant transformed cells without prior sensitization. Engineering NK cells to express chimeric antigen receptors (CARs) allows them to be directed against corresponding target tumor antigens. CAR-NK cells are regarded as a promising candidate for cellular immunotherapy alternatives to conventional CAR-T cells, due to the relatively low risk of graft-versus-host disease and safer clinical profile. Human induced pluripotent stem cells (iPSCs) are a promising renewable cell source of clinical NK cells. In the present study, we successfully introduced a third-generation CAR targeting CD19, which was validated to have effective signaling domains suitable for NK cells, into umbilical cord blood NK-derived iPSCs, followed by a single-cell clone selection and thorough iPSC characterization. The established single-cell clone of CAR19-NK/iPSCs, which is highly desirable for clinical application, can be differentiated using serum- and feeder-free protocols into functional CAR19-iNK-like cells with improved anti-tumor activity against CD19-positive hematologic cancer cells when compared with wild-type (WT)-iNK-like cells. With the feasibility of being an alternative source for off-the-shelf CAR-NK cells, a library of single-cell clones of CAR-engineered NK/iPSCs targeting different tumor antigens may be created for future clinical application.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies
    Cao, Jun-Xia
    Gao, Wei-Jian
    You, Jia
    Wu, Li-Hua
    Liu, Jin-Long
    Wang, Zheng-Xu
    CYTOTHERAPY, 2019, 21 (07) : 769 - 781
  • [22] Development of Anti-CD19 Chimeric Antigen Receptor T-Cells with Immune Checkpoint Silencing
    Matthes, Thomas
    Roussel-Gervais, Audrey
    Salmon, Patrick
    Ilmjarv, Sten
    Sakic, Antonija
    Krause, Karl-Heinz
    Alessandrini, Marco
    MOLECULAR THERAPY, 2021, 29 (04) : 312 - 312
  • [23] Development and in vivo evaluation of anti-CD19 chimeric antigen receptor (CAR) -yδt cells
    Kim, Nayoung
    Kim, Hyery
    Im, Ho Joon
    Koh, Kyung-Nam
    TISSUE ENGINEERING PART A, 2022, 28 : 278 - 278
  • [24] A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor-positive cells
    Ruella, Marco
    Barrett, David M.
    Shestova, Olga
    Perazzelli, Jessica
    Posey, Avery D., Jr.
    Hong, Seok Jae
    Kozlowski, Miroslaw
    Lacey, Simon F.
    Melenhorst, J. Joseph
    June, Carl H.
    Gill, Saar, I
    BLOOD, 2020, 135 (07) : 505 - 509
  • [25] Targeting TIM3 by chimeric antigen receptor-natural killer cells for eradication of acute myeloid leukemia cells
    Klaihmon, Phatchanat
    Samart, Parinya
    Rojanasakul, Yon
    Issaragrisil, Surapol
    Luanpitpong, Sudjit
    CANCER SCIENCE, 2025, 116 : 310 - 310
  • [26] PRDM1 knockout chimeric antigen receptor-natural killer cells exhibit durable anti-tumor efficacy
    Nakashima, Takahiro
    Yoshikawa, Toshiaki
    Matsukawa, Tetsuya
    Ito, Yusuke
    Inoue, Satoshi
    Iida, Shinsuke
    Kagoya, Yuki
    CANCER SCIENCE, 2025, 116 : 98 - 98
  • [27] Generation of functional human thymic cells from induced pluripotent stem cells
    Ramos, Stephan A.
    Morton, John J.
    Yadav, Prabha
    Reed, Brendan
    Alizadeh, Sheila, I
    Shilleh, Ali H.
    Perrenoud, Loni
    Jaggers, James
    Kappler, John
    Jimeno, Antonio
    Russ, Holger A.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : 767 - +
  • [28] A Cellular Antidote to Specifically Deplete Anti-CD19 Chimeric Antigen Receptor (CAR19) Positive Cells
    Ruella, Marco
    Barrett, David M.
    Shestova, Olga
    Perazzelli, Jessica
    Posey, Avery D.
    Kozlowski, Miroslaw
    Lacey, Simon F.
    Melenhorst, J. Joseph
    June, Carl H.
    Gill, Saar I.
    BLOOD, 2017, 130
  • [29] Generation and Characterization of Induced Pluripotent Stem Cells from Human Fibroblast Cells
    Huang, Wenjun
    Zeng, Xiaorong
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (16) : C89 - C90
  • [30] Preclinical development of a new type of anti-CD19 chimeric antigen receptor T cells (ARI-0001 cells)
    Castella, Maria
    Boronat, Anna
    Martin-Ibanez, Raquel
    Rodriguez, Vanina
    Caballero, Miguel
    Marzal, Berta
    Castano, Julio
    Bueno, Clara
    Balague, Olga
    Benitez, Daniel
    Ortiz-Maldonado, Valentin
    Baumann, Tycho
    Campo, Elias
    Menendez, Pablo
    Rives, Susana
    Delgado, Julio
    Yague, Jordi
    Perez-Galan, Patricia
    Maria Canals, Josep
    Urbano-Ispizua, Alvaro
    Juan, Manel
    BONE MARROW TRANSPLANTATION, 2018, 53 : 675 - 676